Cite this post as:
Guest Author. EMCrit Guest Post – The good, the bad, and the ugly of the Joint Statement on REBOA by Zaffer Qasim. EMCrit Blog. Published on May 17, 2018. Accessed on April 26th 2024. Available at [https://emcrit.org/emcrit/good-bad-ugly-of-joint-statement-reboa/ ].
Financial Disclosures:
Dr. Scott Weingart, Course Director, reports no relevant financial relationships with ineligible companies.
This episode’s speaker(s), (listed above), report no relevant financial relationships with ineligible companies.
CME Review
Original Release: May 17, 2018
Date of Most Recent Review: Jan 1, 2022
Termination Date: Jan 1, 2025
You finished the 'cast,
Now Join EMCrit!
As a member, you can...
- Get CME hours
- Get the On Deeper Reflection Podcast
- Support the show
- Write it off on your taxes or get reimbursed by your department
.
Get the EMCrit Newsletter
If you enjoyed this post, you will almost certainly enjoy our others. Subscribe to our email list to keep informed on all of the Resuscitation and Critical Care goodness.
This Post was by the EMCrit Crew, published 6 years ago. We never spam; we hate spammers! Spammers probably work for the Joint Commission.
I think that eventually, REBOA will be used by EPs and really everyone.. The problem is, REBOA remains a research device whose optimal use is not known. In fact, I know of a fatality secondary to REBOA from a stick above the inguinal ligament. We dont know who reboa helps, who it hurts, and who it kills. My reading of the joint statement is that until further research is done, only highly integrated systems involved in research should be putting in these devices, and clinicians who will both put the device in AND manage the complications down the line in… Read more »
Thanks for your comments Vamsi
Regarding it being only a research tool – the ship has already sailed and centers are using it clinically in and outside of the academic centers. I agree those using it should contribute to existing trials because there are still more questions than answers, in particular with patient selection. Currently trial enrollment is voluntary – will centers be bold enough to include their bad outcomes as well as their positive ones?
Great article Zaf!
Thanks DJ!
Strong work, Zaf. I greatly appreciate your wisdom on this topic. Maybe I’m overreacting, but I don’t think so– I dropped my longtime ACEP membership over this issue.
Thanks Bill – appreciate you reading it and your comment!